Phenylpiracetam Research Overview (also known as Phenotropil, Carphedon, 4-phenylpiracetam)
Phenylpiracetam, also known as phenotropil or carphedon, is a synthetic racetam produced by adding a phenyl group to the piracetam structure. The modification is associated with greater central nervous system stimulation and reported effects on attention, wakefulness, cold tolerance, and physical performance, but controlled human evidence remains limited. Phenylpiracetam and its pharmacological class are prohibited by the World Anti-Doping Agency (WADA) because of potential stimulant and performance-enhancing effects.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Phenylpiracetam?
Phenylpiracetam is a synthetic derivative of piracetam in which a phenyl group is attached to the parent racetam scaffold. It was developed in Russia during the late twentieth century and has been marketed under names including Phenotropil and Carphedon. The phenyl substitution was intended to alter lipid solubility, tissue distribution, and central nervous system activity compared with piracetam. In practice, users and small clinical reports have described phenylpiracetam as more activating than piracetam, with possible effects on alertness, task engagement, psychomotor performance, and fatigue. It is not approved as a general-purpose cognitive enhancer in many jurisdictions, and product quality can vary substantially when it is obtained outside regulated pharmaceutical channels.
Russian research and clinical use have focused on cognitive impairment, asthenic states, recovery after neurological injury, and tolerance to physically demanding or cold environments. Phenylpiracetam became particularly notable in sports because of reports that it could increase alertness, work capacity, and resistance to cold. WADA lists phenylpiracetam, also called fonturacetam or carphedon, among prohibited stimulants under the Prohibited List. The prohibition applies in competition, and athletes are responsible for substances found in their samples regardless of whether a product was purchased as a supplement. The WADA status should therefore be treated as a practical medical and regulatory warning, not as proof that efficacy has been established for every claimed use.
Research Indications
Cognitive Performance
Attention and task engagement
Phenylpiracetam is investigated as a stimulant-like racetam for effects on alertness, concentration, and performance during cognitively demanding tasks. Controlled human evidence remains limited.
Memory-related processes
Preclinical racetam literature supports investigation of learning and memory mechanisms, but phenylpiracetam-specific clinical confirmation is insufficient.
Fatigue and Resilience
Mental fatigue
Its phenyl substitution is associated with more activating subjective effects than piracetam, prompting interest in fatigue resistance; this is not an established therapeutic indication.
Physical performance interest
Phenylpiracetam is prohibited in sport under World Anti-Doping Agency rules because of its stimulant-related classification, rather than because performance benefits are clinically established.
Neuroprotective Mechanisms
Racetam pharmacology
Racetam compounds have been studied for membrane, neurotransmission, and neuronal-plasticity effects. Translation of these mechanisms to phenylpiracetam outcomes in healthy people is uncertain.
Neurologic recovery research
Small and regionally published studies have explored neurologic applications, but evidence quality, replication, and regulatory review are inadequate for treatment conclusions.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerance assessment | 50 mg | Once, early day | Oral |
| Cognitive-performance research | 100 mg | Once daily | Oral |
| Divided-dose protocols | 100–200 mg/day | 1–2 divided doses | Oral |
| Sublingual community use | 50–100 mg | Once, early day | Sublingual |
Timing
Use is generally studied or reported earlier in the day because activating effects may interfere with sleep. Avoid redosing late in the day, and do not combine with other stimulants when assessing individual response.
Peptide Interactions
May add to jitteriness, anxiety, elevated heart rate, or insomnia. Avoid using both when first evaluating tolerance.
Overlapping wakefulness-promoting effects may increase overstimulation and sleep disruption; controlled interaction data are lacking.
Both are racetams, but combined use has little clinical study. Concurrent use complicates attribution of benefit or adverse effects.
Amphetamine- or methylphenidate-based medicines may have additive cardiovascular and psychiatric adverse effects.
People taking serotonergic, noradrenergic, or dopaminergic psychiatric medication should obtain clinician review because mood activation and interaction data are uncertain.
Avoid combining with alcohol: stimulant-like effects can mask perceived intoxication and increase impaired decision-making.
Reported Research Timeline
01First 30–90 minutes (reported in cited studies): some users report increased alertness or drive; others notice no acute effect. Anxiety, headache, or irritability can also appear early.
022–4 hours: perceived stimulation may be most noticeable. Track concentration alongside heart rate, mood, appetite, and physical tension.
03Same day: late dosing may delay sleep onset or reduce sleep quality, particularly when combined with caffeine or other activating substances.
04Days 3–7 (reported in cited studies): any subjective cognitive benefit should be evaluated against sleep, anxiety, and productivity measures rather than impression alone.
05Weeks 2–4 (reported in cited studies): tolerance, diminishing perceived effects, or cumulative sleep disruption may become apparent. Human long-term safety data are limited.
06Ongoing (reported in cited studies): reassess regularly and discontinue if adverse mood, cardiovascular, or sleep effects outweigh any perceived benefit.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Avoid use during pregnancy or breastfeeding because adequate safety data are unavailable.
Use particular caution with hypertension, arrhythmia, cardiovascular disease, anxiety disorders, bipolar-spectrum illness, or insomnia.
Do not combine with alcohol, recreational stimulants, or multiple stimulant-like supplements.
Review use with a clinician if taking prescription stimulants, antidepressants, antipsychotics, or seizure medicines.
Phenylpiracetam is prohibited in competition under anti-doping rules; athletes should verify current regulations before use.
Seek Medical Attention If:
Chest pain, fainting, severe shortness of breath, or a sustained rapid or irregular heartbeat occurs.
Severe agitation, confusion, hallucinations, mania-like symptoms, or suicidal thoughts develop.
A seizure, severe headache with neurologic symptoms, or marked blood-pressure elevation occurs.
Signs of serious allergy occur, including facial swelling, wheezing, widespread rash, or difficulty breathing.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Request a current COA that identifies the lot number, test date, laboratory, identity method, and measured phenylpiracetam content.
Verified Marker
Independent HPLC or LC-MS identity testing
Prefer documented third-party chromatographic testing rather than a vendor-only statement of purity.
Verified Marker
Heavy-metal and microbiological screening
For powders and capsules, verify testing for lead, arsenic, cadmium, mercury, and appropriate microbial contaminants.
Acceptable Range
Accurate capsule or powder dosing
Capsule label claims should specify milligrams per unit and excipients. Bulk powder requires a calibrated milligram scale; volume scoops are not reliable.
Quality Concern
Unverifiable purity or proprietary blends
Avoid products without a lot-matched COA, with implausibly high purity claims, or with undisclosed stimulant ingredients.
Research Citations
- Piracetam: a review of pharmacological properties and clinical uses
Winblad, B., 2005, CNS Drug Reviews - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Waegemans, T., Wilsher, C. R., Danniau, A., et al., 2002, Dementia and Geriatric Cognitive Disorders - Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders
Malykh, A. G., Sadaie, M. R., 2010, Drugs - The nootropic concept and its prospective implications
Giurgea, C. E., 1982, Drug Development Research
Research Focus
stimulant, physical performance, cold tolerance, cognitive enhancement, dopamine, WADA
Frequently Asked Questions
What should researchers watch for with Phenylpiracetam?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Phenylpiracetam?
First 30–90 minutes (reported in cited studies): some users report increased alertness or drive; others notice no acute effect. Anxiety, headache, or irritability can also appear early.
How is Phenylpiracetam typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →